SRF

Sharpsmart's Patented Innovation Transforms Sharps Waste Treatment

Retrieved on: 
Monday, September 11, 2023
Atmosphere, Carbon footprint, COVID-19, Movement, ERS, Running, SRF, Incineration, NHS, Pharmaceutical industry, Health care, Sewage treatment

In response, Sharpsmart Ltd, a UK healthcare waste management service provider, took a proactive approach to develop a patented innovation that helped redefine the sustainability landscape of healthcare waste and revolutionised sharps waste treatment with a unique solution.

Key Points: 
  • In response, Sharpsmart Ltd, a UK healthcare waste management service provider, took a proactive approach to develop a patented innovation that helped redefine the sustainability landscape of healthcare waste and revolutionised sharps waste treatment with a unique solution.
  • This waste was taking up valuable space on hospital sites, waste treatment facilities, and transfer stations, meanwhile, waste was being continually generated.
  • Since Sharpsmart Ltd got their patented Effluent Retention System up and running in December 2019, they've processed over 8,300 tonnes of sharps waste, helping their healthcare partners to:
    Have peace of mind with a guaranteed sharps waste outlet.
  • Sharpsmart Ltd's paper: The Effluent Retention System: A New Era in Sustainable Sharps Waste Treatment, can be accessed by visiting this link.

Sichenzia Ross Ference LLP and Carmel, Milazzo & Feil, LLP to Combine as Sichenzia Ross Ference Carmel LLP (SRFC)

Retrieved on: 
Wednesday, September 6, 2023
LLP, Culture, CMF, OTC Markets Group, SRFC, Person, Organization, SRF, FINRA, Initial public offering, Knowledge, Family, NYSE, Security (finance)

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP (“SRF”) and Carmel, Milazzo & Feil, LLP (“CMF”) are pleased to announce that the two firms will combine to form Sichenzia Ross Ference Carmel LLP (“SRFC”), a full-service law firm known for its nationally recognized securities and litigation practices, effective October 1, 2023.

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP (“SRF”) and Carmel, Milazzo & Feil, LLP (“CMF”) are pleased to announce that the two firms will combine to form Sichenzia Ross Ference Carmel LLP (“SRFC”), a full-service law firm known for its nationally recognized securities and litigation practices, effective October 1, 2023.
  • Prior to starting Carmel, Milazzo & Feil, Ross Carmel and Chris Milazzo were former long-term members of the Sichenzia Ross Ference team.
  • “We are excited for these two firms to come together and establish one prominent, deeply experienced securities and litigation practice,” said Gregory Sichenzia, founding partner at Sichenzia Ross Ference Carmel.
  • Ross Carmel, a co-founder of CMF, will join Sichenzia Ross Ference Carmel as a name partner.

The Scleroderma Research Foundation (SRF) Launches Conquest Trial Platform to Address Critical Issues in Clinical Development and Enable Advances in Scleroderma Therapeutics

Retrieved on: 
Tuesday, August 1, 2023
General Health, Foundation, Health, Philanthropy, Scleroderma Research Foundation, Drug development, University, Therapy, Atmosphere, Clinical trial, Cancer, British Lung Foundation, ILD, Keck School of Medicine of USC, Research, FVC, CONQUEST, Autoimmunity, Fibrosis, Vital capacity, SRF, Imperial College London, MD, Patient, Autoimmune disease, Vascular disease, Rheumatology, Disease, Frederick, Knowledge, Ecosystem, Respiratory Medicine, British, Pharmaceutical industry, Vaccine, Medicine, Scleroderma, Sanofi

This groundbreaking effort, conceived and led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders -- patients, physician, and drug innovators -- and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF and its pharmaceutical partners expect to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.

Key Points: 
  • The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, “Our commitment to innovation in scleroderma spans basic, translational, and clinical research.
  • The initial run of CONQUEST is expected to enroll approximately 400 patients and trial initiation is targeted for Q4 2023.

Revolutionizing Water Sector: Aquasight's AMP™ Transforms Traditional Asset Management

Retrieved on: 
Thursday, July 20, 2023
AWWA, Workforce, Ageing, EAMS, ROI, SRF, Algorithm, Water, GIS, Asset management

TROY, Mich., July 20, 2023 /PRNewswire/ -- Aquasight Intelligent Water Solutions unveils its groundbreaking upgrades to AMP™, a cloud-based asset management plan designed to address the sector's most pressing issue - aging water infrastructure. Traditional asset management approaches are falling short in providing continuous updates, real-time risk analysis, and streamlined virtual team collaboration, as highlighted by a recent AWWA survey. Aquasight's AMP™ bridges this gap by revolutionizing asset management through intelligent algorithms and advanced functionalities.

Key Points: 
  • Traditional asset management approaches are falling short in providing continuous updates, real-time risk analysis, and streamlined virtual team collaboration, as highlighted by a recent AWWA survey.
  • Aquasight's AMP™ bridges this gap by revolutionizing asset management through intelligent algorithms and advanced functionalities.
  • Aquasight's AMP™ brings asset management into the digital age by combining familiar spreadsheet and GIS-based functionalities with intelligent algorithms.
  • AMP™ differentiates itself from existing Enterprise Asset Management Systems (EAMS) with its robust GIS-based asset risk and capital planning features.

Christoph Nufer joins Dynamics Group as a Partner in Bern

Retrieved on: 
Friday, June 30, 2023
Communication, Partnership, Justice, Politics, Police, Federal Department, Federal, Federal Department of Justice and Police, SRF, Nufer

Dynamics Group, one of Switzerland's leading strategic communications companies, is pleased to welcome Christoph Nufer as a new partner in Bern.

Key Points: 
  • Dynamics Group, one of Switzerland's leading strategic communications companies, is pleased to welcome Christoph Nufer as a new partner in Bern.
  • "I am looking forward to making my network and experience, which is at the interface of media, politics and business, available to the clients of Dynamics Group," says Christoph Nufer about his new challenge.
  • Thierry Meyer, Chairman of the Board of Directors of Dynamics Group said: "We are very pleased to welcome Christoph Nufer to our partnership.
  • Christoph Nufer, Partner +41 79 314 33 55, [email protected]

New Preclinical Data on AI-Generated Target Identified in BenevolentAI and AstraZeneca Collaboration Presented at ATS 2023

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Technology, Health, Pharmaceutical, Communications, Other Science, Research, Software, Artificial Intelligence, Media, Science, Artificial intelligence, Serum response factor, Small RNA, BAI, CRISPR, AI, Euronext, IPF, SRF, Conference, Benevolence, Idiopathic pulmonary fibrosis, AstraZeneca, Medical device

BenevolentAI ​​(Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announces that AstraZeneca presented new preclinical data on an AI-generated target identified in their ongoing collaboration with BenevolentAI.

Key Points: 
  • BenevolentAI ​​(Euronext Amsterdam: BAI), a leader that combines cutting-edge Artificial Intelligence (AI) and science to accelerate biopharma discovery and development, announces that AstraZeneca presented new preclinical data on an AI-generated target identified in their ongoing collaboration with BenevolentAI.
  • The data was presented at the ATS International Conference 2023.
  • The research provides further scientific information on Serum Response Factor (SRF) as a potential target for idiopathic pulmonary fibrosis (IPF).
  • These data indicate that inhibition of SRF-driven transcription of pro-fibrotic genes in lung fibroblasts might deliver antifibrotic efficacy in IPF.

Delta 9 Applauds Manitoba Government on Bill 10 Amendment to Repeal 6% Social Responsibility Fee

Retrieved on: 
Thursday, May 18, 2023
Social responsibility, DN, Delta, Government, SRF, Space Delta 9, Cannabis, TSX, Health, Safety

WINNIPEG, Manitoba, May 17, 2023 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQB: DLTNF) (“Delta 9” or the “Company”), is pleased to support Bill 10 proposed by the Manitoba Conservative Government which would repeal the 6% Social Responsibility Fee (the “SRF”) on gross retail cannabis revenues.

Key Points: 
  • WINNIPEG, Manitoba, May 17, 2023 (GLOBE NEWSWIRE) -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQB: DLTNF) (“Delta 9” or the “Company”), is pleased to support Bill 10 proposed by the Manitoba Conservative Government which would repeal the 6% Social Responsibility Fee (the “SRF”) on gross retail cannabis revenues.
  • During the public consultations on Bill 10, cannabis retailers, including Delta 9, have encouraged the government to waive the fees owed for 2022 and 2023.
  • "We would like to thank the Manitoba Conservative Government and Minister Cullen for proposing the amendment to make the SRF repeal retroactive to January 2022.
  • “When the social responsibility fee is eliminated, Manitoba will have one of the most competitive pricing programs for cannabis in Canada.

EQS-News: Steinhoff International Holdings N.V. : SRF DISTRIBUTION UPDATE

Retrieved on: 
Tuesday, May 9, 2023
Steinhoff, JSE Limited, Global Analyst Research Settlements, SRF, Frankfurt Stock Exchange, News, Security (finance), Insurance, Cryptocurrency

The SRF, with the assistance of the appointed Claims Administrator, has since been hard at work administering and verifying the claims received.

Key Points: 
  • The SRF, with the assistance of the appointed Claims Administrator, has since been hard at work administering and verifying the claims received.
  • The SRF has informed Steinhoff that it will commence with the distribution of cash recoveries to individual and institutional claimants holding valid and accepted claims on a rolling basis as from 10 May 2023.
  • Marcel Windt, Chairperson of the SRF said: “We are extremely pleased to have reached the stage in this process where we are able to distribute payments to eligible claimants.
  • The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Retrieved on: 
Tuesday, April 25, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Retina, Injection, ARVO, DME, AMD, Paratriathlon, Eye, Neovascularization, MBA, Diabetic retinopathy, ROG, Blood, RO, SRF, Patient, CST, Annual general meeting, Phase, IRF, Macular degeneration, Roche, Pharmaceutical industry, Faricimab, Genentech, Ophthalmology

In diabetic macular edema (DME), post-hoc data suggest Vabysmo treatment resulted in faster drying with fewer injections as well as less blood vessel leakage in the macula, the center of the retina, compared to aflibercept.

Key Points: 
  • In diabetic macular edema (DME), post-hoc data suggest Vabysmo treatment resulted in faster drying with fewer injections as well as less blood vessel leakage in the macula, the center of the retina, compared to aflibercept.
  • “Reducing retinal fluid is associated with improved vision,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • Absence of IRF occurred at 48 weeks with Vabysmo versus 84 weeks with aflibercept, corresponding to a fewer number of injections for Vabysmo patients versus aflibercept.
  • Results showed:*
    The macular leakage area in Vabysmo patients was more than 50% smaller compared to aflibercept at 16 weeks.

DataTracks Introduces Smart Roll Forward for ESEF Reporting Solution

Retrieved on: 
Thursday, April 13, 2023
Product design, EU, Page footer, Bank statement, Hans Hassle, Annual, SRF, Annual report, European, Header, Online shopping, ESEF, ESMA, XBRL

AMSTERDAM and LONDON, April 13, 2023 /PRNewswire/ -- DataTracks, a global compliance leader in financial reporting, has launched an updated ESEF solution with the groundbreaking 'Smart Roll Forward' functionality.

Key Points: 
  • AMSTERDAM and LONDON, April 13, 2023 /PRNewswire/ -- DataTracks, a global compliance leader in financial reporting, has launched an updated ESEF solution with the groundbreaking 'Smart Roll Forward' functionality.
  • With the latest Smart Roll Forward (SRF) update, DataTracks offers a solution that covers last-minute changes without any hassles.
  • Smart Roll Forward is the latest feature added to DataTracks' ESEF Reporting solution and complements Rainbow software.
  • Pramodh Vittal, Vice President for Product Design, DataTracks, said, "We are excited to announce the launch of our updated ESEF solution, complete with the game-changing Smart Roll Forward functionality.